Depression is commonly linked to heightened levels of pro-inflammatory markers, emphasizing the importance of addressing this aspect for effective treatment. Current treatment options encompass selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and bioactive compounds from herbal medicine with antidepressant properties. Nevertheless, ensuring adequate drug levels in the brain regions affected by depression poses a challenge. To surmount this obstacle, leveraging drug delivery systems capable of breaching the blood-brain barrier (BBB) has emerged as a promising strategy for administering antidepressants. Nanoformulations (NFs) have shown promise in this regard, facilitating the delivery of antidepressant agents. This examination offers an outline of nose-to-brain delivery using NFs for treating depression, with a focus on enhancing anti-inflammatory and antioxidant effects.
link of study: https://www.igi-global.com/chapter/nose-to-brain-delivery-of-nanoformulations-for-treatment-of-depression/361137
to download citation file you can click the link and export it.
cite chapter:
